This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OCAT Ocata Therapeutics (OCAT) Stock Price, News & Analysis Add Share Share Stock Analysis Stock AnalysisBuy This Stock About Ocata Therapeutics Stock (NASDAQ:OCAT) 30 days 90 days 365 days Advanced Chart Get Ocata Therapeutics alerts:Sign Up Key Stats Today's Range$8.47▼$8.4750-Day Range N/A52-Week Range$3.06▼$8.71VolumeN/AAverage Volume656,469 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. Read More Receive OCAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OCAT Stock News HeadlinesMorphocell Technologies Appoints Dr. Paul K. Wotton to the Board of DirectorsOctober 30, 2024 | finance.yahoo.comGlobal Tooth Regeneration Market Size To Worth USD 8.20 Billion By 2033 | CAGR Of 6.18%August 22, 2024 | finance.yahoo.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative... | InvestorPlace (Ad)Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida dealMay 1, 2024 | finance.yahoo.comHuman Embryonic Stem Cells Market Latest Trends, Demand and Precise Outlook- Orthofix International N.V., Sumanas, Ocata TherapeuticsMay 6, 2023 | marketwatch.comTooth Regeneration Market Emerging Trends till 2031May 3, 2023 | marketwatch.comGlobal Tooth Regeneration Market by [2023-2029] with Revenue OutsourcingApril 28, 2023 | marketwatch.comInduced Pluripotent Stem Cells Market by 2031March 27, 2023 | marketwatch.comSee More Headlines OCAT Stock Analysis - Frequently Asked Questions How were Ocata Therapeutics' earnings last quarter? Ocata Therapeutics (NASDAQ:OCAT) announced its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $0.04 million for the quarter. What other stocks do shareholders of Ocata Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocata Therapeutics investors own include Antares Pharma (ATRS), Anavex Life Sciences (AVXL), Sarepta Therapeutics (SRPT), Athersys (ATHX), Prospect Capital (PSEC), Bristol Myers Squibb (BMY) and Conatus Pharmaceuticals (CNAT). Company Calendar Last Earnings8/06/2015Today8/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:OCAT Previous SymbolOTCMKTS:ACTC CIK1140098 Webwww.ocata.com Phone+1-508-7561212FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:OCAT) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocata Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.